News
-
-
-
PRESS RELEASE
Jaguar Health Makes Submission to EMA Regarding EU Approval Pathway for Canalevia for General Diarrhea in Dogs Based on Data from Completed Study
Jaguar Health, Inc. requests advice from EMA on EU approval pathway for Canalevia® in treating general diarrhea in dogs. Novel non-antibiotic approach targets a significant market gap -
-
-
PRESS RELEASE
Jaguar Health Secures New Patent for Crofelemer in Short Bowel Syndrome, Strengthening Global IP Position Ahead of Additional Clinical Milestones
Jaguar Health, Inc. secures new patent expanding international IP for crofelemer in pediatric intestinal failure disorders, highlighting reductions in parenteral support. Supporting business development plans -
-
-
PRESS RELEASE
In Support of Possible Expedited Approval Pathway for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID), Jaguar Health Submits Amended Protocol to FDA for Ongoing Placebo-Controlled Clinical Trial
Jaguar Health submits amended protocol to FDA for crofelemer in pediatric MVID patients to potentially extend lives and reduce parenteral support by up to 37% -
